RecruitingNCT07227038
Living Well With Advanced Breast Cancer
Sponsor
Ohio State University Comprehensive Cancer Center
Enrollment
50 participants
Start Date
Jan 15, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
This study evaluates the use of supportive care in patients with advanced breast cancer to better understand what has helped them, what has been hard, and what kind of help they still need.
Eligibility
Min Age: 18 Years
Inclusion Criteria15
- \* COHORT 1:
- Diagnosis of stage 4 metastatic breast cancer within the past 5 years
- Never been referred to the LWABC
- Adults age ≥ 18 years
- COHORT 2:
- Diagnosis of stage 4 metastatic breast cancer within the past 5 years
- Have cancelled an appointment with the LWABC
- Adults age ≥ 18 years
- COHORT 3:
- Been seen in the Medical Oncology Clinic at Stephanie Spielman Comprehensive Breast Center (SSCBC) within the past 5 years
- Completed an appointment with the LWABC
- Adults age ≥ 18 years
- COHORT 4:
- Caregivers for ABC patients
- Adults age ≥ 18 years
Exclusion Criteria1
- Patients who cannot provide own informed consent
Interventions
OTHERNon-Interventional Study
Non-interventional study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07227038
Related Trials
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377475 locations
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT0360696730 locations
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT045504944 locations
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT0567320010 locations
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT054227946 locations